Schiffman et al1 have recently developed
a new method for the evaluation of dry eyes that they hope will be of value
when used in future clinical trials. The proposed name is the Ocular Surface Disease Index.
This term, developed by the Outcomes Research Group at Allergan Inc
(Irvine, Calif) to assess dry eyes, is overly broad and should be modified.
Other diseases that characteristically affect much of the ocular surface,
with microbial and allergic origins, would also fall under the proposed index.
Baum JL. Reliability and Validity of a Proposed Dry Eye Evaluation Scheme. Arch Ophthalmol. 2001;119(3):456. doi: